Jackson Laboratory cancer drug spinout Cyteir Therapeutics extended its series B round thanks to investors including Osage University Partners and Novo Holdings.

Cyteir Therapeutics, a US-based synthetic lethal cancer drug spinout of nonprofit research hub Jackson Laboratory, increased its series B round to $75.2m yesterday with $40.2m from investors including spinout-focused investment firm Osage University Partners (OUP).
Pharmaceutical developer Novo Holdings led the round and was joined by its peer Celgene, oncology-focused investment firm Droia Oncology Ventures and VC firms Lightstone Ventures and Venrock.
Venrock previously led the initial $29m close in March 2018 with contributions from Celgene, Lightstone and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?